{"prompt": "['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 3', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND:108168', 'Approval Date: 18-MAY-2018', 'Copyright 2018 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2018N394263_00', '-', '2016N293064_03', 'CONFIDENTIAL', '205864', 'SPONSOR SIGNATORY', 'PPD', '18 May 2018', 'Aili Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Are Unit', 'PPD', '2']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 3', '18-May-2018', 'Amendment 2', '24-Jul-2017', 'Amendment 1', '17-May-2017', 'Original Protocol', '21-Mar-2017', 'Amendment 1: 17-MAY-2017', 'Overall Rationale for the Amendment: This amendment excludes the enrolment of', 'women of childbearing potential and clarifies the testing required for determination of', 'post menopausal status in specific situations.', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Table 1 -', 'Remove pregnancy testing', 'Not required as no longer enrolling', 'Schedule of', 'WOCBP', 'Activities', 'Added missing check', 'marks', 'Error in original protocol', 'Updated screening period', 'Required to allow for screening lab', 'tests', 'Section 6.1', 'Update to only allow females to', 'To remove additional burden on female', 'Inclusion', 'participate if they are not women of', 'subjects of childbearing potential requiring', 'Criteria', 'childbearing potential (WOCBP)', 'additional visits for pregnancy testing only.', 'Section 12.2', 'Update Table 6 - Protocol-', 'Removed pregnancy testing based on the', '- Appendix 2', 'Required Safety Laboratory', 'exclusion of WOCBP', 'Clinical', 'Assessments to remove pregnancy', 'Laboratory', 'testing', 'Tests', 'Section 12.5', 'Adding clarification on', 'Current wording in template is not', '- Appendix 5', 'determination of post', 'clear on testing required', 'Contraceptive', 'menopausal state in the', 'absence of 12 months of', 'Clarification of wording', 'Guidance and', 'Collection of', 'amenorrhea', 'Pregnancy', 'Updated wording to be in', 'Information', 'line with exclusion of', 'WOCBP', '3']\n\n###\n\n", "completion": "END"}